Melanoma Dispatch
2.6K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

NeoStem Presents Data at ASCO Annual Meeting

"NeoStem, Inc., a leader in the emerging cellular therapy industry, today announced results of a pooled analysis indicating that Melapuldencel-T, an investigational patient-specific immunotherapy for metastatic melanoma, may increase survival rates significantly for patients at the most advanced stages of the disease. The findings will be presented on Sunday, June 1 in a poster by Robert O. Dillman, MD, study author and Vice-President, NeoStem Oncology, at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago."


Editor's note: This is a press release from a company that manufactures an immunotherapy treatment for melanoma. The treatment, called Melapuldencel-T, is meant to boost a patient's own immune system to fight cancer. A recent study testing Melapuldencel-T in patients found promising results for the treatment.

Cancer Commons's insight:

NeoStem  |  May 29, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

‘Early Access’ Scheme Unveiled for Innovative Medicines

‘Early Access’ Scheme Unveiled for Innovative Medicines | Melanoma Dispatch | Scoop.it

"People with advanced cancer and other serious illnesses like dementia could soon benefit from early access to innovative and promising treatments.

"The Early Access to Medicines scheme would enable safe and promising drugs to be 'fast tracked' into the NHS before they have even been granted a licence for use.

"The new scheme will allow patients without other treatment options to be given experimental drugs that have not yet been licensed but that have been deemed safe and effective through clinical trials.

"Experts will carry out a rapid analysis of the treatment before labelling it a 'promising innovative medicine'.

"The Medicines and Healthcare products Regulatory Agency (MHRA) will then offer a scientific opinion based on a medicine’s risks and benefits. If the benefits are found to outweigh the risks, doctors will be given the green light to offer the drug to patients."


Editor's Note: This UK program is similar to a program already in place in the US that allows patients to request access to drugs still being tested in clinical trials. Even though so-called "compassionate access" is possible, the process can be quite difficult for patients. Learn more about it  from our blog feature on the topic.

Cancer Commons's insight:

Cancer Research UK  |  Mar 14, 2014

more...
Cancer Commons's curator insight, March 14, 2014 5:10 PM

Cancer Research UK  |  Mar 14, 2014

Cancer Commons's curator insight, March 14, 2014 5:14 PM

Cancer Research UK  |  Mar 14, 2014

Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain

"Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.


"FDA's Fast Track program facilitates the development of drugs intended to treat serious or life‑threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval."

Cancer Commons's insight:

Nasdaq  |  Apr 28, 2014

more...
Cancer Commons's curator insight, April 29, 2014 6:04 PM

Nasdaq  |  Apr 28, 2014

Cancer Commons's curator insight, April 29, 2014 6:05 PM

Nasdaq  |  Apr 28, 2014